Sofie Inc. enters into partnership with AUGMENTICONTM to access AR/MR technology to enhance radiopharmaceutical manufacturing reliability across its US based radiopharmacy network.

Zurich, Switzerland – AUGMENTICONTM, a privately held technology company developing Augmented-/Mixed-Reality (AR-/MR)-tools for a cost-effective, high-quality manufacturing of (radio-)pharmaceuticals, announces the formation of a strategic, non-exclusive development partnership with Sofie Inc. Sofie will use AUGMENTICON`s SHARE- and ASSYST-platforms for tech-transfer processes, the improvement of manufacturing reliability, and quality management/ auditing and the roll-out of certain key companion diagnostics tied to innovative therapies which are expected to become blockbuster brands. The Corona pandemic exposed the vulnerabilities of “just-in-time” manufacturing of radio-pharmaceuticals as well as essential preventive maintenance and repair services world-wide. AUGMENTICON`s SHARE- and ASSYST-platforms will allow each of Sofie’s manufacturing sites access to expert oversight in real-time. Rapid access to maintenance and service support minimizes downtime and improves capacity and manufacturing reliability. AUGMENTICON`s AR-/MR-featured tools provides “expert-to-operator” communication, guided & controlled manufacturing processes, and fully automated documentation (batch record generation) enabling rapid rollout of new products within Sofie’s manufacturing network. “With this cutting-edge technology we will be well positioned to further optimize production capacity, increase manufacturing reliability and continue to improve customer satisfaction at our Totowa based Center of Excellence as well as across our entire network. We’ve been working with the Augmenticon leadership for a long time and our missions are perfectly aligned.” says Philipp Czernin, Chief Revenue Officer of Sofie. Matthias Friebe, Executive Managing Director of AUGMENTICON states: “We are thrilled to enter into this development partnership to further accelerate the implementation and refinement process of the technology with one of the innovation drivers in the field of molecular diagnostics- and therapeutics-manufacturing in the U.S.”

About AUGMENTICON-SHARE/ASSYST – The AR-/MR supported technology enables a fully remote-controlled installation, repair, and maintenance support, reduced response-times, lower costs (e.g. travel & accommodation etc.), and full online documentation. Furthermore, the technology brings a high potential for online-training, thus helps to shorten training time, and ensures smooth radio-labeling w/o batch failures.

About Sofie Biosciences Inc. (Sofie) – SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine. For more information, please visit https://www.sofie.com or contact philipp.czernin@sofie.com

About AUGMENTICONTM AUGMENTICON, a driver in the application of novel INDUSTRY-4.0 solutions offers applications for the optimization of industrial radiopharmaceutical operations. The company, founded in 2019, is based in Glattbrugg/Switzerland and is developing and commercializing Augmented-/Mixed-Reality based tools for a fully remote-controlled manufacturing guidance, -control, and (GMP-)-documentation. It`s management has a combined 60+ years of expertise in the development, manufacturing, release, marketing, and commercialization of (radio-) pharmaceuticals. To learn more about AUGMENTICON please visit us at: https://www.augmenticon.ch.